At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,208 enrolled
Drug / intervention
SIM0417 +1 moredrug
Likely dose
SIM0417 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
In Brief
A Phase 3 clinical trial evaluating SIM0417 and Placebo for COVID-19. Completed, enrolled 1,208 participants across 35 sites.
Detailed Summary
This Phase Ⅱ/Ⅲ study is to evaluate whether or not there is a difference in time recovery of COVID-19 signs and symptoms through Day 29 between SIM0417/ritonavir and placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartAug 2022
Primary CompletionJan 2023
Study CompletionMar 2023
TodayJul 2026
First PostedAug 18, 2022
Enrollment StartAug 19, 2022
Primary CompletionJan 23, 2023
Study CompletionMar 21, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.9 years ago
Interventions
SIM0417drug
dose of 750 mg SIM0417 with 100 mg ritonavir.
Placebodrug
Placebo (tablet)